DYN Insider Trading

Insider Ownership Percentage: 20.77%
Insider Buying (Last 12 Months): $1,057,280.00
Insider Selling (Last 12 Months): $12,878,411.80

Dyne Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Dyne Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$40M-$20M$0$20M$40MTotal Insider BuyingTotal Insider Selling

Dyne Therapeutics Share Price & Price History

Current Price: $9.42
Price Change: Price Decrease of -0.49 (-4.94%)
As of 04/3/2025 05:00 PM ET

This chart shows the closing price history over time for DYN up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMar$9.42Closing price on 04/03/25:

SEC Filings (Institutional Ownership Changes) for Dyne Therapeutics (NASDAQ:DYN)

96.68% of Dyne Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at DYN by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$76Mbought$72MsoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$100M-$50M$0$50M$100MTotal InflowsTotal Outflows
Dyne Therapeutics logo
Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
Read More on Dyne Therapeutics

Today's Range

Now: $9.42
Low: $9.07
High: $9.71

50 Day Range

MA: $12.92
Low: $9.23
High: $16.76

52 Week Range

Now: $9.42
Low: $8.94
High: $47.45

Volume

1,702,902 shs

Average Volume

1,420,250 shs

Market Capitalization

$1.07 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.11

Who are the company insiders with the largest holdings of Dyne Therapeutics?

Dyne Therapeutics' top insider shareholders include:
  1. Jason P Rhodes (Director)
  2. Venture Fund Xi LP Atlas (Major Shareholder)
  3. Dirk Kersten (Director)
  4. Joshua T Brumm (CEO)
  5. Joshua T Brumm (Insider)
  6. Oxana Beskrovnaya (Insider)
  7. Susanna Gatti High (COO)
  8. Wildon Farwell (Insider)
  9. Jonathan Mcneill (Insider)
  10. Richard William Scalzo (Insider)
  11. Richard William Scalzo (SVP)
  12. Johanna Friedl-Naderer (Insider)
  13. John Cox (CEO)
  14. Carlo Incerti (Director)
Learn More about top insider investors at Dyne Therapeutics.